wfvd9c95

Property	Value
?:abstract	Clinical manifestations of COVID-19 are varied in the general population. This study aimed to systematize the literature regarding clinical manifestations of patients with confirmed COVID-19. A systematic review of the literature was conducted. A total of 8070 scientific productions were found in the databases. Among the studies, 184 met the initial inclusion criteria, with a total of 114,046 patients. After complete reading, 32 studies that did not report clinical manifestations were excluded. The 152 publications finally included a total of 41,409 individuals from at least 23 countries and 26 different clinical manifestations were reported. In percentage terms, 6 symptoms had a general prevalence greater than or equal to 25%, namely, fever (58.66%), cough (54.52%), dyspnea (30.82%), malaise (29.75%), fatigue (28.16%) and sputum/secretion (25.33%). Neurological symptoms (20.82%), dermatological manifestations (20.45%), anorexia (20.26%), myalgia (16.9%), sneezing (14.71%), sore throat (14.41%), rhinitis (14.29%), goosebumps (13.49%), headache (12.17%), chest pain (11.49%) and diarrhea (9.59%) were other common symptoms. Only one study reported dermatological manifestations. The least frequent sign/symptom was hemoptysis (1.65%). In studies with more than 100 patients, the 3 main symptoms were fever (57.93%), cough (54.21%), and dyspnea (30.64%). Dermatological manifestations do not appear among the main symptoms. The identification of all clinical manifestations of COVID-19 is essential for an early diagnosis and the adoption of preventive measures. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00508-020-01760-4) contains supplementary material, which is available to authorized users.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/wfvd9c95_hasAnnotation_C0008031> <https://research.tib.eu/covid-19/entity/wfvd9c95_hasAnnotation_C0010200> <https://research.tib.eu/covid-19/entity/wfvd9c95_hasAnnotation_C0011991> <https://research.tib.eu/covid-19/entity/wfvd9c95_hasAnnotation_C0013404> <https://research.tib.eu/covid-19/entity/wfvd9c95_hasAnnotation_C0015672> <https://research.tib.eu/covid-19/entity/wfvd9c95_hasAnnotation_C0015967> <https://research.tib.eu/covid-19/entity/wfvd9c95_hasAnnotation_C0018681> <https://research.tib.eu/covid-19/entity/wfvd9c95_hasAnnotation_C0019079> <https://research.tib.eu/covid-19/entity/wfvd9c95_hasAnnotation_C0037088> <https://research.tib.eu/covid-19/entity/wfvd9c95_hasAnnotation_C0037383> <https://research.tib.eu/covid-19/entity/wfvd9c95_hasAnnotation_C0231218> <https://research.tib.eu/covid-19/entity/wfvd9c95_hasAnnotation_C0231528> <https://research.tib.eu/covid-19/entity/wfvd9c95_hasAnnotation_C0235031> <https://research.tib.eu/covid-19/entity/wfvd9c95_hasAnnotation_C1457887>
?:creator	<https://research.tib.eu/covid-19/entity/da_Rosa_Mesquita%2C_Rodrigo%3B_Francelino_Silva_Junior%2C_Luiz_Carlos%3B_Santos_Santana%2C_Fernanda_Mayara%3B_Farias_de_Oliveira%2C_Tatiana%3B_Campos_Alc%C3%A2ntara%2C_Rafaela%3B_Monteiro_Arnozo%2C_Gabriel%3B_Rodrigues_da_Silva_Filho%2C_Etvaldo%3B_Galdino_dos_Santos%2C_Aisla_Graciele%3B_Oliveira_da_Cunha%2C_Euclides_Jos%C3%A9%3B_Salgueiro_de_Aquino%2C_Saulo_Henrique%3B_Freire_de_Souza%2C_Carlos_Dornels>
?:doi	10.1007/s00508-020-01760-4
?:doi	<https://research.tib.eu/covid-19/entity/10.1007/s00508-020-01760-4>
?:journal	Wien_Klin_Wochenschr
?:license	no-cc
?:pdf_json_files	document_parses/pdf_json/dfa1c02512aa9d80aa04587382905be14ccf0856.json
?:pmc_json_files	document_parses/pmc_json/PMC7689634.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7689634>
?:pmid	<https://research.tib.eu/covid-19/entity/33242148.0>
?:pmid	33242148.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/dfa1c02512aa9d80aa04587382905be14ccf0856>
?:source	Medline; PMC
?:title	Clinical manifestations of COVID-19 in the general population: systematic review
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-26

Property

Value

?:abstract

Clinical manifestations of COVID-19 are varied in the general population. This study aimed to systematize the literature regarding clinical manifestations of patients with confirmed COVID-19. A systematic review of the literature was conducted. A total of 8070 scientific productions were found in the databases. Among the studies, 184 met the initial inclusion criteria, with a total of 114,046 patients. After complete reading, 32 studies that did not report clinical manifestations were excluded. The 152 publications finally included a total of 41,409 individuals from at least 23 countries and 26 different clinical manifestations were reported. In percentage terms, 6 symptoms had a general prevalence greater than or equal to 25%, namely, fever (58.66%), cough (54.52%), dyspnea (30.82%), malaise (29.75%), fatigue (28.16%) and sputum/secretion (25.33%). Neurological symptoms (20.82%), dermatological manifestations (20.45%), anorexia (20.26%), myalgia (16.9%), sneezing (14.71%), sore throat (14.41%), rhinitis (14.29%), goosebumps (13.49%), headache (12.17%), chest pain (11.49%) and diarrhea (9.59%) were other common symptoms. Only one study reported dermatological manifestations. The least frequent sign/symptom was hemoptysis (1.65%). In studies with more than 100 patients, the 3 main symptoms were fever (57.93%), cough (54.21%), and dyspnea (30.64%). Dermatological manifestations do not appear among the main symptoms. The identification of all clinical manifestations of COVID-19 is essential for an early diagnosis and the adoption of preventive measures. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00508-020-01760-4) contains supplementary material, which is available to authorized users.

is ?:annotates of